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Abstract: Background and Aims: Up to 6% of colorectal cancers (CRC) are 
diagnosed within 5 years of a colonoscopy that did not diagnose CRC 
(post-colonoscopy colorectal cancer, PCCRC). PCCRC and associated risk 
factors were examined within a national hospital episode database. 
 
Methods: A retrospective case-control study of all adult colonoscopies 
recorded in Hospital Episode Statistics (HES) between 2003-2009 in 
England. PCCRC cases underwent colonoscopy 6-60 months before diagnosis; 
controls had not undergone colonoscopy 6-60 months before diagnosis. 
Multivariate logistic regression analysis examined associations with 
PCCRC. 
 
Results: 1,439,684 colonoscopies were analysed, including 67,202 CRC and 
8147 (12.1%) PCCRC cases. Multivariate analysis revealed that female 
gender (odds ratio 1.13 (95% CI 1.08-1.19), p<0.001), older age (70-74 
years) (1.09 (1.00-1.18), p=0.039), increased co-morbidity (Charlson 
index 5+) (1.16 (1.05-1.28), p<0.003) and right sided CRC (1.17 (1.11-
1.23), p<0.0001) were associated with PCCRC. Emergency colonoscopy (0.54 
(0.59-0.69), p<0.0001) was negatively associated with PCCRC. More PCCRC 
subjects developed metastases within 12 months and less underwent surgery 
(0.33 (0.32-0.35), p<0.0001) or chemotherapy (0.66 (0.62-0.69), 
p<0.0001). PCCRC rates varied twofold between providers, and was 
associated with medium volume providers compared with high volume (1.13 
(1.01-1.27), p=0.035). The PCCRC rate fell from 13.8% in 2003 to 11.9% in 
2009. 
 
Conclusions: PCCRC occurred in 12.1% of CRC patients between 2003 and 
2009. PCCRC was associated with female gender, older age, increased co-
morbidity, right sided CRC, elective procedures and colonoscopy volume. 
PCCRC was associated with worse outcomes. 
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Abstract 
 
Background and Aims: Up to 6% of colorectal cancers (CRCs) are diagnosed within 5 years of 
a colonoscopy that did not diagnose CRC (post-colonoscopy colorectal cancer, PCCRC). 
PCCRC and associated risk factors were examined within a national hospital episode 
database. 
 
Methods: A retrospective case-control study of all adult colonoscopies recorded in Hospital 
Episode Statistics (HES) between 2003 and 2009 in England. PCCRC cases underwent 
colonoscopy 6 to 60 months before diagnosis; controls had not undergone colonoscopy 6 to 
60 months before diagnosis. Multivariate logistic regression analysis examined associations 
with PCCRC. 
 
Results: A total of 1,439,684 colonoscopies were analyzed, including 67,202 CRC and 8147 
(12.1%) PCCRC cases. Multivariate analysis revealed that female gender (odds ratio [OR], 
1.13; (95% CI, 1.08-1.19), p<0.001), older age (70-74 years) (OR, 1.09; 95% CI, 1.00-1.18), 
p=0.039), increased co-morbidity (Charlson index 5+) (OR, 1.16; 95% CI, 1.05-1.28), p<0.003) 
and right-sided CRC (OR, 1.17; 95% CI, 1.11-1.23), p<0.0001) were associated with PCCRC. 
Emergency colonoscopy (OR, 0.54; 95% CI, 0.59-0.69), p<0.0001) was negatively associated 
with PCCRC. More PCCRC subjects developed metastases within 12 months and fewer 
underwent surgery (OR, 0.33; 95% CI, 0.32-0.35), p<0.0001) or chemotherapy (OR, 0.66; 
95% CI, 0.62-0.69), p<0.0001). PCCRC rates varied twofold between providers and was 
associated with medium volume providers compared with high volume (OR, 1.13; 95% CI, 
1.01-1.27), p=0.035). The PCCRC rate fell from 13.8% in 2003 to 11.9% in 2009. 
 
Conclusions: PCCRC occurred in 12.1% of CRC patients between 2003 and 2009. PCCRC was 
associated with female gender, older age, increased co-morbidity, right-sided CRC, elective 
procedures, and colonoscopy volume. PCCRC was associated with worse outcomes. 
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Introduction 
 
Colonoscopy is the criterion standard for diagnosing, screening and surveillance for CRC. In 
England, the setting of national standards for colonoscopy and accreditation of endoscopy 
units has resulted in an improvement in auditable colonoscopy standards over the last 
decade.[1] The same period has also coincided with an increase in 5-year survival after CRC 
diagnosis from 47.8% to 53.6%.[2] However, 2.6% to 6.0% of CRC patients have previously 
been reported to be diagnosed within 5 years of a colonoscopy that did not detect cancer. 
These events are termed post-colonoscopy colorectal cancer (PCCRC).[3, 4, 5] It has been 
proposed that PCCRC may have a different cell biology from other CRC with more aggressive 
and rapidly growing tumors.[6, 7] However, 2 recently published North American studies 
concluded that this did not apply to the majority of PCCRC, with around two-thirds of PCCRC 
a result of missed lesions or incomplete polypectomy.[4, 8] 
 
Given the improvements in colonoscopy over the past decade in England, we have 
examined the impact on PCCRC in a national hospital episode database and associated risk 
factors for these events. 
 
Methods 
 
Data sources 
Hospital Episode Statistics (HES) is an administrative database that records information on 
all elective and emergency care episodes in National Health Service (NHS) hospitals in 
England.[9] Each care episode record includes demographic, admission, diagnoses and 
procedures data. Diagnoses are coded using International Classification of Diseases version 
10 (ICD-10) and procedures are coded using Office of Population Censuses and Surveys 
Classification of Interventions and Procedures 4th revision (OPCS-4). HES is linked to Office 
for National Statistics (ONS) mortality records, which include date of death and causes of 
death recorded on death certificates. The NHS provides comprehensive healthcare coverage 
for the UK population, with the vast majority of colonoscopies performed in the UK by a 
NHS provider.[1] 
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Subject definitions 
 
All subjects over the age of 18 years undergoing colonoscopy between April 2003 and March 
2009 were identified from HES. Colonoscopy and CRC were defined by OPCS-4 (appendix 1) 
and ICD-10 codes (appendix 2) respectively. Subjects with a CRC diagnosis before the first 
episode of colonoscopy and subjects with a diagnosis of inflammatory bowel disease (IBD) 
were excluded from the analysis to avoid confounding through surveillance. 
 
Recording of a CRC diagnosis in HES records may be delayed by a few weeks from the date 
of the diagnostic colonoscopy code.[10, 11] For the purpose of this study, the diagnosis date 
was therefore defined as the first colonoscopy code during the 6 months before the first 
CRC coding episode in HES or mortality records[10, 12], or the first CRC episode for those 
subjects who did not have a colonoscopy during this 6-month period due to being diagnosed 
through an alternative method, eg, barium enema, CT colonography or flexible 
sigmoidoscopy. Subjects undergoing colonoscopy 6 to 60 months before subsequent CRC 
diagnosis were identified as PCCRC cases. These cases were further classified as PCCRC 6 to 
12 months (colonoscopy 6 to 12 months before CRC diagnosis); PCCRC 12 to 36 months 
(colonoscopy 12 to 36 months before CRC diagnosis) and PCCRC 36 to 60 months 
(colonoscopy 36 to 60 months before CRC diagnosis). For patients who had more than one 
colonoscopy 6 to 60 months before CRC diagnosis, data from the most recent colonoscopy 
was used for analysis. Controls were subjects who had not undergone colonoscopy in the 
period 6 to 60 months before CRC diagnosis. Colonoscopies from 2003 to 2009 were studied 
to ensure all subjects had at least 5 years of follow-up within HES. The PCCRC rate was 
calculated from the number of PCCRC subjects divided by the sum of PCCRC subjects and 
controls.[13] 
 
Validation of colonoscopy and colorectal cancer populations 
To assess the validity of the HES colonoscopy population, the number of colonoscopies 
between 2007 and 2010 at University Hospital Birmingham (UHB) was extracted from 
endoscopy records (Unisoft Medical Systems, Enfield, Middlesex, UK) and compared with 
the number of colonoscopies recorded in HES for UHB. To assess the validity of a CRC 
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diagnosis in HES using the study methodology, the number of HES CRC cases was compared 
with the number of CRC cases diagnosed in England from the National Cancer Intelligence 
Network (NCIN)[14] from 2002 to 2011. Finally, the rate of surgery in the HES CRC 
population was compared with rate of surgery in the National Bowel Cancer Audit between 
2008 and 2011.[15, 16, 17] 
 
Study variables 
 
Subject demographics 
Study variables were extracted from coding at the time of PCCRC colonoscopy in cases and 
diagnostic colonoscopy or first CRC episode in controls. Ethnicity was identified from HES 
demographic fields and grouped into White or White British, Asian or Asian British, Black or 
Black British, Chinese, Mixed and other ethnic groups. 
 
Co-morbidity 
The Charlson co-morbidity index was calculated using ICD-10 codes for secondary diagnoses, 
excluding metastatic disease, and divided into 3 categories: 0 (no co-morbidity), 1 to 4 (low 
co-morbidity) and 5 or greater (high co-morbidity).[18] 
 
Socio-economic status 
Deprivation was assessed using the Index of Multiple Deprivations 2007, which is an 
aggregate score for each English catchment area. Subjects were linked to their 
corresponding catchment area by postcode of residence and associations with deprivation 
were analyzed in quintiles, with quintile 1 being the most deprived. 
 
Colorectal cancer variables 
CRC site was classified based on the first CRC coding episode into right sided, left sided, and 
unspecified (appendix 3). Coding records of initially unspecified site CRC were examined and 
if a more specific code had been used subsequently, this was used to determine the CRC 
site. Colonic polyps were identified from ICD-10 codes (appendix 4). 
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Distant metastases were identified by ICD-10 codes (appendix 5) up to 12 months from 
diagnosis date and were used as a surrogate marker of CRC stage at diagnosis, as Dukes’ 
staging is not recorded in HES. Codes for metastases can occasionally be miscoded as a 
primary neoplasm (eg, lung), and therefore primary malignancy codes were also used, 
provided that they were recorded in the 12 months subsequent to CRC diagnosis (appendix 
5). Surgery and chemotherapy were identified by respective OPCS-4 codes (appendix 6). 
 
Survival analysis 
Survival analysis adjusted for gender, age, deprivation, and co-morbidity was calculated 
from the CRC diagnosis date of PCCRC cases and controls using date of death from ONS. 
Subjects who were not diagnosed by colonoscopy were not included to avoid potential lead 
time bias due to the method of determining date of diagnosis from HES. 
 
Provider variables 
For the purpose of this study, all endoscopy units operating within the same NHS 
organisation were analysed as a single provider. Individual providers were stratified by 
colonoscopy volume, bowel cancer screening program (BCSP) status and the percentage of 
CRCs diagnosed during an emergency rather than an elective episode to determine if there 
was an association with PCCRC. Colonoscopy volume was determined from the total number 
of colonoscopies performed during the study period at each provider and separated into 
tertiles. A BCSP accredited provider had at least one endoscopy unit accredited with BCSP 
status by the end of the study period. The percentage of CRCs diagnosed as an emergency at 
a provider was the ratio of CRCs diagnosed during an acute (unplanned) admission divided 
by all CRCs, including CRCs diagnosed during an elective episode. 
 
Ethics 
As only pseduonymized information was used in this study, ethics approval was not 
necessary. HES data are available under a data-sharing agreement for the purposes of 
service evaluation. 
 
Statistical methodology 
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Statistical analysis was carried out with STATA SE v13.1 (Statacorp LP, Tex, USA). Analysis of 
variance and χ2 tests were used to compare differences in continuous and categorical 
variables respectively. Associations with PCCRC were examined by univariate and 
multivariate logistic regression. A multivariate model was constructed to determine 
associations with PCCRC after adjusting for gender, age, Charlson co-morbidity index, 
procedure type (emergency or elective), CRC site (left side of colon or right side of colon), 
metastases, and procedure year. For tests of significance, p values <0.05 were considered 
significant. All odds ratios, 95% confidence intervals, and associated p values are the result 
of multivariate analysis unless stated otherwise. Unadjusted Kaplan-Meier analysis and Cox 
proportional hazards modeling after adjustment for gender, age, deprivation, and co-
morbidity were used to compare survival in PCCRC cases and controls. 
 
Results 
 
Study cohort 
Between April 2003 and March 2009, 1,439,684 colonoscopies were identified and 67,202 
subjects were diagnosed with CRC during this period. Out of the 67,202 CRC subjects, there 
were 8147 (12.1%) PCCRC subjects: 1796 (2.7%) PCCRC 6 to 12 months; 3772 (5.6%) PCCRC 
12 to 36 months, and 2579 (3.8%) PCCRC 36 to 60 months. A total of 59,055 CRC subjects 
had not had a colonoscopy between 6 and 60 months before CRC diagnosis and served as 
controls. Overall, 0.66% or 1 in every 150 subjects developed PCCRC after a colonoscopy 
that did not diagnose CRC. 
 
Validation of colonoscopy and colorectal cancer populations 
The total number of colonoscopies carried out between 2007 and 2010 at UHB was 8708 
and 8292 colonoscopies (95.2%) were coded in HES for UHB for the equivalent 4-year 
period. The CRC population was validated by comparing CRC cases recorded in HES 
(315,515) to CRC cases reported from 2002 to 2011 by NCIN (312,984)[14], showing a 
concordance of over 99%. The CRC population was further validated by comparing the 
70.4% surgical rate for CRC from HES with the National Bowel Cancer Audit, which reported 
that 75.7% of CRC patients enrolled in the audit underwent surgery between 2008 and 
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2011.[15, 16, 17] All of the validation processes showed a good correlation between HES 
data and independent data sources, suggesting the study methodology was valid. 
 
Subject characteristics 
The characteristics of cases with PCCRC and CRC controls are shown in Table 1. PCCRC 
subjects (mean age 70.7 ± 11.4 years) were older than controls (mean age 70.2 ± 11.4 
years)(p<0.001). The risk of PCCRC appeared to increase with age on univariate analysis, but 
only subjects aged 70 to 74 were associated with PCCRC compared with subjects under 60, 
after adjusting for confounding factors. PCCRC subjects were more likely to be female. 
Subjects with the most co-morbidities (Charlson co-morbidity index of 5 or greater) were 
associated with PCCRC. PCCRC was not associated with differences in ethnicity or 
deprivation. 
 
Colonoscopy variables and findings 
The influence of colonoscopy variables and findings on PCCRC are shown in Table 2. The 
majority of CRC were diagnosed during an elective colonoscopy. However, being diagnosed 
during an emergency colonoscopy reduced the risk of PCCRC nearly by half. There was 
minor increased risk of PCCRC on univariate analysis in colonoscopies carried out at the 
weekend compared with during the week. 
 
PCCRC was more likely to be associated with CRC in the right side of the colon. Colonic 
polyps were coded in 21.6% of the colonoscopies that did not detect CRC in the PCCRC 
group. Polypectomy was coded in a further 18.9%.  On univariate analysis, this was higher 
than both the recorded polyp rate of 9.8% (2.52 (95% CI, 2.39-2.65), p<0.0001) and 
polypectomy rate of 11.3% (1.82 (95% CI, 1.72-1.92), p<0.0001) from all colonoscopies 
during the study period. Furthermore, the polyp and polypectomy rates were both higher in 
the PCCRC 6 to 12 months group on univariate analysis, than in the PCCRC 12 to 36 months 
(p<0.0001), and PCCRC 36 to 60 months (p<0.0001) groups.  
 
Colorectal outcomes and survival  
The prevalence of metastatic disease within 12 months of CRC diagnosis in PCCRC cases and 
controls are shown in Table 3. PCCRC cases were up to twice as likely to be diagnosed with 
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lung, peritoneal, and bone metastases within 12 months of CRC diagnosis. However, lymph 
node metastases were more prevalent in controls than PCCRC cases, suggesting coding bias 
related to the increased rate of surgery in control subjects described later. 
 
On univariate analysis, PCCRC cases were less likely to undergo surgery compared with 
controls (0.33 (95% CI, 0.32-0.35), p<0.0001) or chemotherapy (0.66 (95% CI, 0.62-0.69), 
p<0.0001). Overall survival was also worse in PCCRC subjects compared with controls, with a 
median survival of 5.8 years in controls compared with 2.1 years in the PCCRC 6- to 12-
month group, 2.0 years in the PCCRC 12- to 36-month group, and 3.5 years in the PCCRC 36- 
to 60-month group (figure 1). after adjusting for age, gender, co-morbidity, and deprivation, 
survival outcomes remained worse for PCCRC subjects with a hazard ratio of 1.17 (95% CI, 
1.10- 1.24)(p<0.0001), 1.26 (95% CI, 1.20-1.31)(p<0.0001) and 1.20 (95% CI, 1.13-
1.27)(p<0.0001) for the PCCRC 6 to 12 months, PCCRC 12 to 36 months, and PCCRC 36 to 60 
months respectively when compared with controls. 
 
Individual provider variables 
The influence of provider variables on PCCRC are shown in Table 4. There was a more than 
twofold variation in PCCRC rates between individual providers in England during the study 
period (figure 2). On univariate analysis, medium colonoscopy volume providers and low 
volume providers were both more likely to be associated with PCCRC than high volume 
providers. after adjusting for other variables in the multivariate model an association with 
medium volume providers remained. BCSP accreditation status and the percentage of CRC 
diagnosed as an emergency were not associated with an increased risk of PCCRC. 
 
PCCRC rates over time 
The number of colonoscopies recorded in HES has increased by almost 2-fold over the study 
period. Despite the increase in colonoscopy numbers performed year on year, the annual 
rate of PCCRC has steadily fallen over the study period (p<0.0001)(figure 3). The annual 
PCCRC rate decreased from 13.8% in 2003 to 2004 to 11.9% by the end of study period in 
2008 to 2009 with the reduction seen mainly in the PCCRC 6- to 12-month and PCCRC 12- to 
36-month groups. 
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Discussion 
 
The overall PCCRC rate of 12.1% in 67,202 subjects in England between 2003 and 2009 
appears higher than previously published figures. However, some previous studies have 
calculated the PCCRC rate by only including CRC subjects with a colonoscopy up to 36 
months before diagnosis and the comparable figure from the present study is 8.3%. A 
Canadian study of 14,064 CRC subjects reported a PCCRC rate of 9.0% between 2000 and 
2005.[12] Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database 
in the USA, a PCCRC rate of 7.2% was reported between 1994 to 2005 from a study of 
57,839 CRC subjects.[19] A further population based study from Utah, USA, with 2659 CRC 
subjects between 1995 and 2009 described a PCCRC rate of 6% when subjects with a 
colonoscopy up to 60 months before CRC diagnosis were included.[4] In Europe, 2 recent 
studies have reported much lower PCCRC rates. A Danish population based study between 
2000 to 2009 included 37,044 CRC subjects and concluded that only 2.7% of CRC subjects 
have had a colonoscopy that failed to diagnose CRC 1 to 5 years before diagnosis.[5] A 
second study from the Netherlands analyzed 5107 CRC subjects between 2001 to 2010 from 
three providers and found a PCCRC rate of only 2.9% for subjects with a colonoscopy up to 
60 months before CRC diagnosis.[20] In addition to potential variations in subject and 
colonoscopy factors between the difference studies, the wide range of reported PCCRC 
rates are likely to be contributed to by methodological differences.[13] 
 
In the present study, PCCRC was associated with older subjects, female gender, an increased 
number of co-morbidities and right-sided CRC, which is in keeping with findings from other 
studies of PCCRC. [3, 12, 19, 21] The association between increasing age and PCCRC was less 
marked on multivariate analysis and this may relate to confounding from increasing co-
morbidity in the elderly. Elderly patients are more likely to have inadequate bowel 
preparation, thus reducing mucosal visualisation and detection of polyps and early CRC.[22, 
23] Female patients are more likely to have had previous abdominal and pelvic surgery, 
which may increase the technical difficulty of colonoscopy and impair patient tolerance, 
reducing the cecal intubation rate.[24] In addition to factors that have an adverse effect on 
cecal intubation rate, right-sided CRC are more likely to arise from flat, non-polypoid 
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adenomatous lesions[20, 25] that poor bowel preparation may make difficult to detect. This 
will contribute to the association of right-sided CRC with PCCRC. 
 
Over a fifth of PCCRC subjects had colonic polyps or polypectomy coded during the most 
recent colonoscopy before CRC diagnosis. This is higher than the average polypectomy rate 
in all colonoscopy procedures during the same period. Furthermore, polyp and polypectomy 
coding rates were highest in the PCCRC 12- to 36-month group. Prior polypectomy has been 
reported to double the risk of PCCRC[19], with up to 19% of CRCs occurring in the same 
anatomic segment as a previously resected adenoma.[8] Paradoxically, colonoscopists with 
higher polypectomy rates have been reported to be associated with a lower risk of 
PCCRC[12, 19], presumably as they detect more polyps and remove them more completely 
than other colonoscopists. Incomplete polypectomy, or inadequate biopsy sampling of 
polyps, is therefore a key modifiable risk factor for PCCRC and ensuring adequate follow-up 
and assessment after polypectomy may reduce PCCRC rates. 
 
PCCRC subjects appeared to have worse outcomes in terms of both treatment after 
diagnosis (surgery and chemotherapy) and overall survival. Previous studies have reported 
no survival difference between PCCRC subjects and controls[5, 21] with one recent study 
even reporting a survival benefit in the PCCRC subjects, which was likely to be due to earlier 
CRC stage at diagnosis in the PCCRC subjects.[4] In the current study, PCCRC subjects were 
older, had greater co-morbidities and were more likely to present with distant metastases 
within 12 months of diagnosis compared with controls. All these factors contributed to the 
reduced rates of curative surgery or palliative chemotherapy for PCCRC subjects and will 
have contributed to worse survival. Adjusting the survival analyses for differences in ages, 
gender, co-morbidity and deprivation still revealed worse survival for PCCRC subjects and, at 
least in England, PCCRC is clearly associated with worse survival.  Survival in PCCRC subjects 
would have been potentially better if earlier opportunities to diagnose their CRC had been 
taken.  
 
Previous studies have reported that PCCRC was not associated with endoscopist procedure 
volume[12] and that higher colonoscopy volumes may even be positively associated with 
PCCRC surprisingly.[19] In the current study, there was a large variation in PCCRC rates 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  12 
between individual providers across England but PCCRC appeared to be associated with 
lower colonoscopy volume providers. This result should be interpreted with caution. We did 
not have access to colonoscopy quality indicators such as cecal intubation and adenoma 
detection rates that are likely to be potentially more important factors in PCCRC incidence.  
 
Colonoscopy undertaken during an emergency admission covered 10% of procedures 
examined and was associated with a lower risk of PCCRC at 9% compared with 14% for 
elective procedures. Patients presenting as an emergency may have more advanced 
colorectal cancer and therefore a lower chance of PCCRC.  
 
The annual PCCRC rate in England has fallen steadily over the study period from 13.8% to 
11.9%, at least partly due to improving colonoscopy standards over the corresponding time 
period. In 2003, a multi-regional audit in England including 9223 colonoscopies reported 
that mean cecal intubation rate was only 76.9%.[26] A subsequent national audit in 2011 of 
20085 colonoscopies found that the cecal intubation rate had improved to 92.3%.[1] The 
PCCRC rate is likely to continue to improve in recent years given changes in colonoscopy 
practice, including the recognition of the importance of minimum withdrawal times [27], 
bowel preparation improvements[28], and better endoscopic recognition of sessile serrated 
polyps[25], subsequent to the study period. 
 
The use of a national hospital dataset enabled us to undertake one of the largest PCCRC 
studies to date, including the vast majority of colonoscopies performed during a period of 
rising colonoscopy standards. The quality of diagnostic and procedural coding in HES has 
been previously investigated and there was a high concordance when compared with 
independent national data sources.[1, 10, 29] However, we did not have the opportunity to 
link our HES dataset directly to cancer registry data due to restrictions under which the data 
is held and therefore, in order to validate the methodology chosen, colonoscopy and CRC 
populations were compared with national cancer databases and a local data sample and 
revealed a good correlation. The completeness and accuracy of coding in HES is still a 
potential source of concern. For example, the diagnosis date may not be recorded 
accurately in HES due to the need for histological confirmation before CRC coding and 
therefore a colonoscopy within 6 months of CRC coding had to be considered the diagnostic 
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procedure. There are also limitations in HES concerning coding of colonoscopy procedures, 
polyps, polypectomy, presence of metastases, surgery and chemotherapy and the figures 
included may be an over or under estimate, though this is likely to affect PCCRC cases and 
controls equally. A further limitation is that key procedure information such as the bowel 
preparation quality, sedation doses, colonoscopist grade and specialty, extent of 
examination, completeness of polypectomy, and number of biopsy specimens taken are not 
recorded in HES and all may influence the PCCRC risk. Furthermore, due to the HES coding 
hierarchy, indication, presence of diverticular disease and history of abdominal or pelvic 
surgery may not be coded, partly due to under-reporting by colonoscopists when significant 
pathology or CRC are found and again each may be important risk factors for PCCRC. As HES 
does not record polyp histology or the International Classification of Diseases for Oncology 
(ICD-O) codes, the lack of data on polyp and CRC histology and Duke’s staging further limits 
analysis of potential causes of PCCRC (de novo CRC, incomplete adenoma resection, missed 
lesion or biopsy failed to detect CRC), and survival in PCCRC subjects. 
 
In conclusion, the PCCRC rate was 12.1% in England between 2003 and 2009. PCCRC was 
associated with older age, female gender, increasing co-morbidity, procedure related 
factors (elective procedures and right-sided CRC), and provider colonoscopy volume. 
Despite the encouraging fall in annual PCCRC rate over the study period, the PCCRC rate 
should be a routinely measured endoscopy unit colonoscopy quality marker, and potentially 
avoidable risk factors for PCCRC should be addressed. 
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Table 1. The characteristics of post-colonoscopy colorectal cancer cases and controls 
 
PCCRC 6-
12 months 
PCCRC 12-
36 months 
PCCRC 36-
60 months 
All PCCRC Controls 
Odds 
ratio 
95% CI P value 
Odds 
ratio 
95% CI P value 
Total subjects (number) Univariate Multivariate 
 1796 (2.7) 3772 (5.6) 2579 (3.8) 8147 (12.1) 59055 (87.9) - - - - - - 
Mean age SD (years) 
 71.5±11.4 70.9±11.7 69.8±10.8 70.7±11.4 70.2±11.4 - - <0.001    
Age group (number (%))    
Under 60 263 (3.2) 598 (7.3) 415 (5.1) 1276 (15.7) 9849 (16.7) Ref      
60-64 167 (2.0) 367 (4.5) 288 (3.5) 822 (10.1) 6749 (11.4) 0.94 0.86-1.03 0.1928 0.95  0.86-1.04 0.277 
65-69 217 (2.7) 531 (6.5) 435 (5.3) 1183 (14.5) 8810 (14.9) 1.04 0.95-1.13 0.4044 1.03  0.94-1.12 0.537 
70-74 344 (4.2) 648 (8.0) 488 (6.0) 1480 (18.2) 10229 (17.3) 1.12 1.03-1.21 0.0067 1.09  1.00-1.18 0.039 
75-79 359 (4.4) 678 (8.3) 499 (6.1) 1536 (18.9) 10698 (18.1) 1.11 1.02-1.20 0.0109 1.07  0.98-1.16 0.159 
80+ 446 (5.5) 950 (11.7) 454 (5.6) 1850 (22.7) 12720 (21.5) 1.12 1.04-1.21 0.0029 1.08  1.00-1.17 0.065 
Gender (number (%)) 
Male 974 (12.0) 1974 (24.2) 1340 (16.4) 4288 (52.6) 33057 (56.0) Ref - - Ref - - 
Female 822 (10.1) 1798 (22.1) 1239 (15.2) 3859 (47.4) 25998 (44.0) 1.14 1.09-1.20 <0.0001 1.13 1.08-1.19 <0.001 
Charlson co-morbidity index (number (%)) 
0 1514 (18.6) 3210 (39.4) 2235 (27.4) 6959 (85.4) 50663 (85.8) Ref - - Ref - - 
1-4 154 (1.9) 298 (3.7) 210 (2.6) 662 (8.1) 4764 (8.1) 1.01 0.93-1.10 0.7896 1.06  0.97-1.16 0.195 
5+ 128 (1.6) 264 (3.2) 134 (1.6) 526 (6.5) 3628 (6.1) 1.06 0.96-1.16 0.2641 1.16  1.05-1.28 0.003 
Deprivation quintile (number (%)) 
1 (most) 329 (4.0) 637 (7.8) 393 (4.8) 1359 (16.7) 10015 (17.0) Ref - - - - - 
2 365 (4.5) 740 (9.1) 499 (6.1) 1604 (19.7) 11258 (19.1) 1.05 0.97-1.13 0.2153 - - - 
3 333 (4.1) 782 (9.6) 551 (6.8) 1666 (20.4) 12399 (21.0) 0.99 0.91-1.07 0.8002 - - - 
4 387 (4.8) 784 (9.6) 568 (7.0) 1739 (21.3) 12642 (21.4) 1.01 0.94-1.09 0.7242 - - - 
5 (least) 381 (4.7) 823 (10.1) 566 (6.9) 1770 (21.7) 12620 (21.4) 1.03 0.96-1.11 0.3905 - - - 
Ethnicity (number (%)) 
White 
1656 
(20.3) 
3536 (43.4) 2467 (30.3) 7659 (94.0) 54512 (92.3) Ref - - - - - 
Asian 21 (0.3) 55 (0.7) 36 (0.4) 112 (1.4) 788 (1.3) 1.01 0.83-1.23 0.9097 - - - 
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Afro-
Caribbean 
25 (0.3) 53 (0.7) 27 (0.3) 105 (1.3) 823 (1.4) 0.91 0.74-1.11 0.3553 - - - 
Chinese 0 0 0 12 (0.1) 118 (0.2) 0.72 0.40-1.30 0.2865 - - - 
Mixed 0 0 0 18 (0.2) 160 (0.3) 0.80 0.49-1.30 0.3719 - - - 
Others 12 (0.1) 21 (0.3) 21 (0.3) 54 (0.7) 341 (0.6) 1.13 0.85-1.50 0.4156 - - - 
Unknown 74 (0.9) 95 (1.2) 18 (0.2) 187 (2.3) 2313 (3.9) 0.58 0.49-0.67 <0.0001 - - - 
Odds ratios with 95% confidence intervals and p values for PCCRC (all) compared with controls 
PCCRC – post-colonoscopy colorectal cancer 
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Table 2. The colonoscopy characteristics and findings of post-colonoscopy colorectal cancer cases and controls 
 
PCCRC 6-12 
months 
PCCRC 12-
36 months 
PCCRC 36-60 
months 
All PCCRC Controls 
Odds 
ratio 
95% CI P value 
Odds 
ratio 
95% CI P value 
Procedure day (number (%)) Univariate Multivariate 
Weekday 1736 (21.3) 3628 (44.5) 2486 (30.5) 7850 (96.4) 57249 (96.9) Ref - - - - - 
Weekend 60 (0.7) 144 (1.8) 93 (1.1) 297 (3.6) 1806 (3.1) 1.19 1.06-1.36 0.0044 - - - 
Procedure type (number (%))    
Elective 1622 (19.9) 3473 (42.6) 2455 (30.1) 7550 (92.7) 52605 (89.1) Ref - - Ref - - 
Emergency 174 (2.1) 299 (3.7) 124 (1.5) 597 (7.3) 6450 (10.9) 0.64 0.59-0.70 <0.0001 0.54 0.59-0.69 <0.0001 
Colorectal cancer location (number (%))    
Left sided 897 (11.0) 1754 (21.5) 1260 (15.5) 3911 (48.0) 34703 (58.8) Ref - - Ref - - 
Right sided 535 (6.6) 1242 (15.2) 919 (11.3) 2696 (33.1) 20751 (35.1) 1.15 1.09-1.21 <0.0001 1.17  1.11-1.23 <0.0001 
Unknown/ 
overlapping sites 
364 (4.5) 776 (9.5) 400 (4.9) 1540 (18.9) 3601 (6.1) 3.79 3.54-4.06 <0.0001 3.72  3.46-3.99 <0.0001 
Polyp/ polypectomy coded (number (%))    
Polyp coded 491 (6.0) 742 (9.1) 523 (6.4) 1756 (21.6) 141799* (9.8) 2.52+ 2.39-2.65+ <0.0001+ - - - 
No polyp coded 1305 (16.0) 3030 (37.2) 2056 (25.2) 6391 (78.4) 1300714* (90.2) Ref - - - - - 
Polypectomy coded 348 (4.3) 669 (8.2) 523 (6.4) 1540 (18.9) 162364* (11.3) 1.82+ 1.72-1.92+ <0.0001+ - - - 
No polypectomy 
coded 
1448 (17.8) 3103 (38.1) 2056 (25.2) 6607 (81.1) 1280150* (89.7) Ref - - - - - 
Odds ratios with 95% confidence intervals and p values for all PCCRC compared with controls 
PCCRC – post-colonoscopy colorectal cancer 
* From all colonoscopies 
+ Univariate analysis comparing all PCCRC with all colonoscopies during study period. 
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Table 3. The prevalence of metastases within 12 months of colorectal cancer diagnosis in post-colonoscopy colorectal cancer cases and controls 
 
PCCRC 6-12 
months 
PCCRC 12-36 
months 
PCCRC 36-60 
months 
All PCCRC Controls 
Odds 
ratio 
95% CI p value 
Odds 
ratio 
95% CI P value 
Subjects with metastases within 12 months of diagnosis (number (%)) Univariate Multivariate 
Liver metastases 276 (3.4) 619 (7.6) 365 (4.5) 1260 (15.5) 8545 (14.5) 1.08 1.01-1.15 0.017 0.97  0.91-1.05 0.486 
Lung metastases 154 (1.9) 345 (4.2) 182 (2.2) 681 (8.4) 3104 (5.3) 1.64 1.51-1.79 <0.0001 1.61  1.46-1.77 <0.0001 
Peritoneal 
metastases 
75 (0.9) 166 (2.0) 102 (1.3) 343 (4.2) 1903 (3.2) 1.32 1.17-1.48 <0.0001 1.27  1.12-1.44 <0.0001 
Bone metastases 45 (0.6) 106 (1.3) 78 (1.0) 229 (2.8) 678 (1.1) 2.49 2.14-2.90 <0.0001 2.21  1.88-2.60 <0.0001 
Lymph node 
metastases 
136 (1.7) 282 (3.5) 231 (2.8) 649 (8.0) 6459 (10.9) 0.70 0.65-0.76 <0.0001 0.75  0.69-0.82 <0.0001 
Treatment outcome after diagnosis (number (%))    
Surgery 791 (9.7) 1661 (20.4) 1337 (16.4) 3789 (46.5) 42790 (72.5) 0.33 0.32-0.35 <0.0001 - - - 
Chemotherapy 422 (5.2) 911 (11.2) 594 (7.3) 1927 (23.7) 18908 (32.0) 0.66 0.62-0.69 <0.0001 - - - 
Odds ratios with 95% confidence intervals and P values for PCCRC (all) compared with controls. 
PCCRC – post-colonoscopy colorectal cancer. 
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Table 4. The influence of provider variables on post-colonoscopy colorectal cancer 
 
PCCRC 6-12 
months 
PCCRC 12-
36 months 
PCCRC 36-60 
months 
All PCCRC Controls 
Odds 
ratio 
95% CI p value 
Odds 
ratio 
95% CI P value 
Colonoscopy volume by NHS provider (number (%)) Univariate Multivariate 
High volume providers 
(>1680 pa) 
955 (11.7) 1993 (24.5) 1415 (17.4) 4363 (53.6) 33353 (56.5) Ref - - Ref - - 
Medium volume providers 704 (8.6) 1486 (18.2) 994 (12.2) 3184 (39.1) 21942 (37.2) 1.11 1.06-1.16 <0.0001 1.13 1.01-1.27 0.035 
Low-volume providers (<747 
pa) 
137 (1.7) 293 (3.6) 170 (2.1) 600 (7.4) 3760 (6.4) 1.22 1.11-1.34 <0.0001 1.05  0.98-1.12 0.161 
BCSP status (number (%)) 
BCSP provider 959 (11.8) 2064 (25.3) 1396 (17.1) 4419 (54.2) 31780 (53.8) Ref - - - - - 
Non-BCSP provider 837 (10.3) 1708 (21.0) 1183 (14.5) 3728 (45.8) 27275 (46.2) 0.98 0.94-1.03 0.4690 0.96  0.90-1.03 0.255 
Percentage of CRC diagnosed during an emergency admission by NHS provider (number (%)) 
Low-percentage providers 
(<27.3%) 
408 (5.0) 848 (10.4) 629 (7.7) 1885 (23.1) 14270 (24.2) 0.91 0.84-0.98 0.0115 0.96  0.87- 1.06 0.443 
Medium percentage 
providers 
1068 (13.1) 2273 (27.9) 1530 (18.8) 4871 (59.8) 35211 (59.6) 0.95 0.89-1.01 0.1299 0.96  0.85-1.09 0.531 
High-percentage providers 
(>33.9%) 
320 (3.9) 651 (8.0) 420 (5.2) 1391 (17.1) 9572 (16.2) Ref - - Ref - - 
Odds ratios with 95% confidence intervals and p values for PCCRC (all) compared with controls 
PCCRC – post-colonoscopy colorectal cancer 
BCSP – Bowel Cancer Screening Program 
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Figure 1. Post-colonoscopy colorectal cancer rates by individual provider in England 
between 2003 and 2009. 
 
Figure 2. Unadjusted survival after colorectal cancer diagnosis in post-colonoscopy 
colorectal cancer cases and control subjects. 
 
Figure 3 Post-colonoscopy colorectal cancer rates and colonoscopy volume in England by 
year. 
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Appendix 1 - OPCS-4 codes for colonoscopy 
H20.1 Snare polypectomy 
H20.6 Polypectomy with colonoscopy 
H22.1 Diagnostic fibreoptic endoscopic examination of colon and biopsy of lesion of colon 
H22.8 Other specified diagnostic endoscopic examination of colon 
H22.9 Unspecified diagnostic endoscopic examination of colon 
 
Appendix 2 - ICD-10 codes for colorectal cancers 
C18 Malignant neoplasm of colon - excluding C18.1 (malignant neoplasm of appendix) 
C19 Malignant neoplasm of rectosigmoid junction 
C20 Malignant neoplasm of rectum 
 
Appendix 3 – ICD-10 codes for colorectal cancer (CRC) sites 
Right sided CRC 
C18.0 Caecum, Ileocaecal valve 
C18.2 Ascending colon 
C18.3 Hepatic flexure 
C18.4 Transverse colon 
 
Left sided CRC 
C18.5 Splenic flexure 
C18.6 Descending colon 
C18.7 Sigmoid colon 
C19 Rectosigmoid junction 
C20 Rectum 
 
Unspecified CRC location 
C18.8 Overlapping lesion of colon 
C18.9 Colon, unspecified 
 
Appendix 4 - ICD-10 codes for colorectal polyps 
D12.0 Caecal polyp(s) 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  21 
D12.2 Ascending colon polyp(s) 
D12.3 Transverse colon, hepatic flexure, splenic flexure polyp(s) 
D12.4 Descending colon polyp(s) 
D12.5 Sigmoid colon polyp(s) 
D12.6 Colon, site unspecified polyp(s) 
D12.7 Rectosigmoid junction polyp(s) 
D12.8 Rectal polyp(s) 
 
Appendix 5 - ICD-10 codes for metastases 
C77.1 Intrathoracic lymph nodes 
C77.2 Intra-abdominal lymph nodes 
C77.4 Inguinal and lower limb lymph nodes 
C77.5 Intrapelvic lymph nodes 
C78.0 Secondary malignant neoplasm of lung 
C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum 
C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct 
C79.5 Secondary malignant neoplasm of bone and bone marrow 
C34 Malignant neoplasm of bronchus and lung 
C48 Malignant neoplasm of retroperitoneum and peritoneum 
C22 Malignant neoplasm of liver 
C40-C41 Malignant neoplasms of bone and articular cartilage 
 
Appendix 6- OPCS-4 codes for surgical procedures 
H04 Total excision of colon and rectum 
H05 Total excision of colon 
H06 Extended excision of right hemicolon 
H07 Other excision of right hemicolon 
H08 Excision of transverse colon 
H09 Excision of left hemicolon 
H10 Excision of sigmoid colon 
H11 Other excision of colon 
H29 Subtotal excision of colon 
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H33 Excision of rectum 
H40 Operations on rectum through anal sphincter 
H122 Excision of lesion of colon NEC 
H123 Destruction of lesion of colon NEC 
H128 Other specified extirpation of lesion of colon 
H129 Unspecified extirpation of lesion of colon 
H341 Open excision of lesion of rectum 
H345 Open destruction of lesion of rectum 
H348 Other specified open extirpation of lesion of rectum 
H349 Unspecified open extirpation of lesion of rectum 
H402 Trans-sphincteric excision of lesion of rectum 
H403 Trans-sphincteric destruction of lesion of rectum 
OPCS-4 codes for chemotherapy 
X70 Procurement of drugs for chemotherapy for neoplasm in Bands 1-5 
X71 Procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
X72 Delivery of Chemotherapy for neoplasm 
X73 Delivery of oral chemotherapy for neoplasm 
X352 Intravenous chemotherapy 
X384 Subcutaneous chemotherapy 
X373 Intramuscular chemotherapy 
Z082 Follow up examination after chemotherapy for malignant neoplasm 
Z511 Chemotherapy session for neoplasm 
Z542 Convalescence following chemotherapy 
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Dear Drs. Wallace and Gross, 
 
Re – GIE-D-15-01290: How often does colonoscopy fail to diagnose colorectal cancer (retrospective 
analysis of English Hospital Episode Statistics from 2003 to 2009)? 
 
Thank you very much for sending your further editorial comments and requesting review and 
resubmission of our manuscript. We have detailed below our responses to the editorial comments 
and related amendments to the paper.  
 
Editorial comments 
 
In the first paragraph of the discussion we explain the potential reasons for our reported PCCRC rate 
of 12.1% appearing higher than other published studies. The most important reason is that we chose 
to study PCCRC for five years after colonoscopy, rather than three years as some studies have done. 
Using a three year follow up period after colonoscopy, our PCCRC rate of 8.3% is consistent with other 
studies as we discuss.    
 
Unfortunately, we are unable to provide the data requested for the period 2010 to 2014. This time 
period would not allow five years of follow up within the database to ascertain whether colorectal 
cancer developed following the colonoscopy. 
 
However, the rate of PCCRC fell during the period we studied and we do accept the point made that 
there have been a number of advances in colonoscopy in recent years that should impact further on 
the rate of PCCRC in recent years when it is subsequently analysed. We have amended the discussion 
to acknowledge that the current PCCRC rate is likely to be even lower than the reported PCCRC rate in 
our study due to changes in colonoscopy practice. Text amended. 
 
We hope our manuscript is now suitable for publication. 
 
 
Yours sincerely, 
 
 
Dr Nigel Trudgill 
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Abstract 
 
Background and Aims: Up to 6% of colorectal cancers (CRC) are diagnosed within 5 years of 
a colonoscopy that did not diagnose CRC (post-colonoscopy colorectal cancer, PCCRC). 
PCCRC and associated risk factors were examined within a national hospital episode 
database. 
 
Methods: A retrospective case-control study of all adult colonoscopies recorded in Hospital 
Episode Statistics (HES) between 2003-2009 in England. PCCRC cases underwent 
colonoscopy 6-60 months before diagnosis; controls had not undergone colonoscopy 6-60 
months before diagnosis. Multivariate logistic regression analysis examined associations 
with PCCRC. 
 
Results: 1,439,684 colonoscopies were analysed, including 67,202 CRC and 8147 (12.1%) 
PCCRC cases. Multivariate analysis revealed that female gender (odds ratio 1.13 (95% CI 
1.08-1.19), p<0.001), older age (70-74 years) (1.09 (1.00-1.18), p=0.039), increased co-
morbidity (Charlson index 5+) (1.16 (1.05-1.28), p<0.003) and right sided CRC (1.17 (1.11-
1.23), p<0.0001) were associated with PCCRC. Emergency colonoscopy (0.54 (0.59-0.69), 
p<0.0001) was negatively associated with PCCRC. More PCCRC subjects developed 
metastases within 12 months and less underwent surgery (0.33 (0.32-0.35), p<0.0001) or 
chemotherapy (0.66 (0.62-0.69), p<0.0001). PCCRC rates varied twofold between providers, 
and was associated with medium volume providers compared with high volume (1.13 (1.01-
1.27), p=0.035). The PCCRC rate fell from 13.8% in 2003 to 11.9% in 2009. 
 
Conclusions: PCCRC occurred in 12.1% of CRC patients between 2003 and 2009. PCCRC was 
associated with female gender, older age, increased co-morbidity, right sided CRC, elective 
procedures and colonoscopy volume. PCCRC was associated with worse outcomes. 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  3 
Introduction 
 
Colonoscopy is the gold standard for diagnosing, screening and surveillance for CRC. In 
England, the setting of national standards for colonoscopy and accreditation of endoscopy 
units has resulted in an improvement in auditable colonoscopy standards over the last 
decade.[1] The same period has also coincided with an increase in 5 year survival following 
CRC diagnosis from 47.8% to 53.6%.[2] However, 2.6 to 6.0% of CRC patients have 
previously been reported to be diagnosed within 5 years of a colonoscopy which did not 
detect cancer. These events are termed post-colonoscopy colorectal cancer (PCCRC).[3, 4, 5] 
It has been proposed that PCCRC may have a different cell biology from other CRC with 
more aggressive and rapidly growing tumours.[6, 7] However, two recently published North 
American studies concluded that this did not apply to the majority of PCCRC, with around 
two thirds of PCCRC a result of missed lesions or incomplete polypectomy.[4, 8] 
 
Given the improvements in colonoscopy over the past decade in England, we have 
examined the impact on PCCRC in a national hospital episode database and associated risk 
factors for these events. 
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Methods 
 
Data sources 
Hospital Episode Statistics (HES) is an administrative database which records information on 
all elective and emergency care episodes in National Health Service (NHS) hospitals in 
England.[9] Each care episode record includes demographic, admission, diagnoses and 
procedures data. Diagnoses are coded using International Classification of Diseases version 
10 (ICD-10) and procedures are coded using Office of Population Censuses and Surveys 
Classification of Interventions and Procedures 4th revision (OPCS-4). HES is linked to Office 
for National Statistics (ONS) mortality records, which include date of death and causes of 
death recorded on death certificates. The NHS provides comprehensive healthcare coverage 
for the UK population, with the vast majority of colonoscopies performed in the UK by a 
NHS provider.[1] 
 
Subject definitions 
 
All subjects over the age of 18 years undergoing colonoscopy between April 2003 and March 
2009 were identified from HES. Colonoscopy and CRC were defined by OPCS-4 (appendix 1) 
and ICD-10 codes (appendix 2) respectively. Subjects with a CRC diagnosis prior to the first 
episode of colonoscopy and subjects with a diagnosis of inflammatory bowel disease (IBD) 
were excluded from the analysis to avoid confounding through surveillance. 
 
Recording of a CRC diagnosis in HES records may be delayed by a few weeks from the date 
of the diagnostic colonoscopy code.[10, 11] For the purpose of this study, the diagnosis date 
was therefore defined as the first colonoscopy code during the 6 months prior to the first 
CRC coding episode in HES or mortality records[10, 12], or the first CRC episode for those 
subjects who did not have a colonoscopy during this 6 month period due to being diagnosed 
through an alternative method, e.g. barium enema, CT colonography or flexible 
sigmoidoscopy. Subjects undergoing colonoscopy 6 to 60 months before subsequent CRC 
diagnosis were identified as PCCRC cases. These cases were further classified as PCCRC 6-12 
months (colonoscopy 6 to 12 months prior to CRC diagnosis); PCCRC 12-36 months 
(colonoscopy 12 to 36 months prior to CRC diagnosis) and PCCRC 36-60 months 
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(colonoscopy 36 to 60 months prior to CRC diagnosis). For patients who had more than one 
colonoscopy 6 to 60 months prior to CRC diagnosis, data from the most recent colonoscopy 
was used for analysis. Controls were subjects who had not undergone colonoscopy in the 
period 6 to 60 months before CRC diagnosis. Colonoscopies from 2003 to 2009 were studied 
to ensure all subjects had at least 5 years of follow up within HES. The PCCRC rate was 
calculated from the number of PCCRC subjects divided by the sum of PCCRC subjects and 
controls.[13] 
 
Validation of colonoscopy and colorectal cancer populations 
To assess the validity of the HES colonoscopy population, the number of colonoscopies 
between 2007 and 2010 at University Hospital Birmingham (UHB) was extracted from 
endoscopy records (Unisoft Medical Systems, Enfield, Middlesex, UK) and compared with 
the number of colonoscopies recorded in HES for UHB. To assess the validity of a CRC 
diagnosis in HES using the study methodology, the number of HES CRC cases was compared 
with the number of CRC cases diagnosed in England from the National Cancer Intelligence 
Network (NCIN)[14] from 2002 to 2011. Finally, the rate of surgery in the HES CRC 
population was compared with rate of surgery in the National Bowel Cancer Audit between 
2008 and 2011.[15, 16, 17] 
 
Study variables 
 
Subject demographics 
Study variables were extracted from coding at the time of PCCRC colonoscopy in cases and 
diagnostic colonoscopy or first CRC episode in controls. Ethnicity was identified from HES 
demographic fields and grouped into White or White British, Asian or Asian British, Black or 
Black British, Chinese, Mixed and other ethnic groups. 
 
Co-morbidity 
The Charlson co-morbidity index was calculated using ICD-10 codes for secondary diagnoses, 
excluding metastatic disease, and divided into three categories: 0 (no co-morbidity), 1-4 
(low co-morbidity) and 5 or greater (high co-morbidity).[18] 
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Socio-economic status 
Deprivation was assessed using the Index of Multiple Deprivations 2007, which is an 
aggregate score for each English catchment area. Subjects were linked to their 
corresponding catchment area by postcode of residence and associations with deprivation 
were analysed in quintiles, with quintile 1 being the most deprived. 
 
Colorectal cancer variables 
CRC site was classified based on the first CRC coding episode into: right sided, left sided and 
unspecified (appendix 3). Coding records of initially unspecified site CRC were examined and 
if a more specific code had been used subsequently, this was used to determine the CRC 
site. Colonic polyps were identified from ICD-10 codes (appendix 4). 
 
Distant metastases were identified by ICD-10 codes (appendix 5) up to 12 months from 
diagnosis date and were used as a surrogate marker of CRC stage at diagnosis, as Dukes’ 
staging is not recorded in HES. Codes for metastases can occasionally be miscoded as a 
primary neoplasm (e.g. lung), and therefore primary malignancy codes were also used, 
provided that they were recorded in the 12 months subsequent to CRC diagnosis (appendix 
5). Surgery and chemotherapy were identified by respective OPCS-4 codes (appendix 6). 
 
Survival analysis 
Survival analysis adjusted for gender, age, deprivation and co-morbidity was calculated from 
the CRC diagnosis date of PCCRC cases and controls using date of death from ONS. Subjects 
who were not diagnosed by colonoscopy were not included to avoid potential lead time bias 
due to the method of determining date of diagnosis from HES. 
 
Provider variables 
For the purpose of this study, all endoscopy units operating within the same NHS 
organisation were analysed as a single provider. Individual providers were stratified by 
colonoscopy volume, bowel cancer screening program (BCSP) status and the percentage of 
CRC diagnosed during an emergency rather than an elective episode to determine if there 
was an association with PCCRC. Colonoscopy volume was determined from the total number 
of colonoscopies performed during the study period at each provider and separated into 
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tertiles. A BCSP accredited provider had at least one endoscopy unit accredited with BCSP 
status by the end of the study period. The percentage of CRC diagnosed as an emergency at 
a provider was the ratio of CRC diagnosed during an acute (unplanned) admission divided by 
all CRC, including CRC diagnosed during an elective episode. 
 
Ethics 
As only pseduonymised information was used in this study, ethics approval was not 
necessary. HES data is available under a data sharing agreement for the purposes of service 
evaluation. 
 
Statistical methodology 
Statistical analysis was carried out with STATA SE v13.1 (Statacorp LP, Texas, USA). Analysis 
of variance and χ2 tests were used to compare differences in continuous and categorical 
variables respectively. Associations with PCCRC were examined by univariate and 
multivariate logistic regression. A multivariate model was constructed to determine 
associations with PCCRC following adjusting gender, age, Charlson co-morbidity index, 
procedure type (emergency or elective), CRC site (left colon or right colon), metastases and 
procedure year. For tests of significance, p values <0.05 were considered significant. All odds 
ratios, 95% confidence intervals and associated p values are the result of multivariate 
analysis unless stated otherwise. Unadjusted Kaplan-Meier analysis and Cox proportional 
hazards modelling following adjustment for gender, age, deprivation and co-morbidity were 
used to compare survival in PCCRC cases and controls. 
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Results 
 
Study cohort 
Between April 2003 and March 2009, 1,439,684 colonoscopies were identified and 67,202 
subjects were diagnosed with CRC during this period. Out of the 67,202 CRC subjects, there 
were 8,147 (12.1%) PCCRC subjects: 1796 (2.7%) PCCRC 6-12 months; 3,772 (5.6%) PCCRC 
12-36 months and 2,579 (3.8%) PCCRC 36-60 months. 59,055 CRC subjects had not had a 
colonoscopy between 6 and 60 months prior to CRC diagnosis and served as controls. 
Overall, 0.66% or 1 in every 150 subjects developed PCCRC after a colonoscopy that did not 
diagnose CRC. 
 
Validation of colonoscopy and colorectal cancer populations 
The total number of colonoscopies carried out between 2007 and 2010 at UHB was 8708 
and 8292 colonoscopies (95.2%) were coded in HES for UHB for the equivalent four year 
period. The CRC population was validated by comparing CRC cases recorded in HES 
(315,515) to CRC cases reported from 2002 to 2011 by NCIN (312,984)[14], showing a 
concordance of over 99%. The CRC population was further validated by comparing the 
70.4% surgical rate for CRC from HES with the National Bowel Cancer Audit, which reported 
that 75.7% of CRC patients enrolled in the audit underwent surgery between 2008 and 
2011.[15, 16, 17] All of the validation processes showed a good correlation between HES 
data and independent data sources, suggesting the study methodology was valid. 
 
Subject characteristics 
The characteristics of cases with PCCRC and CRC controls are shown in Table 1. PCCRC 
subjects (mean age 70.7±11.4 years) were older than controls (mean age 70.2±11.4 
years)(p<0.001). The risk of PCCRC appeared to increase with age on univariate analysis, but 
only subjects aged 70 to 74 were associated with PCCRC compared with subjects under 60, 
following adjusting for confounding factors. PCCRC subjects were more likely to be female. 
Subjects with the most co-morbidities (Charlson co-morbidity index of 5 or greater) were 
associated with PCCRC. PCCRC was not associated with differences in ethnicity or 
deprivation. 
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Colonoscopy variables and findings 
The influence of colonoscopy variables and findings on PCCRC are shown in Table 2. The 
majority of CRC were diagnosed during an elective colonoscopy. However, being diagnosed 
during an emergency colonoscopy reduced the risk of PCCRC nearly by half. There was 
minor increased risk of PCCRC on univariate analysis in colonoscopies carried out at the 
weekend compared with during the week. 
 
PCCRC was more likely to be associated with CRC in the right colon. Colonic polyps were 
coded in 21.6% of the colonoscopies which did not detect CRC in the PCCRC group. 
Polypectomy was coded in a further 18.9%.  On univariate analysis, this was higher than 
both the recorded polyp rate of 9.8% (2.52 (95% CI 2.39-2.65), p<0.0001) and polypectomy 
rate of 11.3% (1.82 (95% CI 1.72-1.92), p<0.0001) from all colonoscopies during the study 
period. Furthermore, the polyp and polypectomy rates were both higher in the PCCRC 6-12 
months group on univariate analysis, than in the PCCRC 12-36 months (p<0.0001) and 
PCCRC 36-60 months (p<0.0001) groups.  
 
Colorectal outcomes and survival  
The prevalence of metastatic disease within 12 months of CRC diagnosis in PCCRC cases and 
controls are shown in Table 3. PCCRC cases were up to twice as likely to be diagnosed with 
lung, peritoneal and bone metastases within 12 months of CRC diagnosis. However, lymph 
node metastases were more prevalent in controls than PCCRC cases, suggesting coding bias 
related to the increased rate of surgery in control subjects described later. 
 
On univariate analysis, PCCRC cases were less likely to undergo surgery compared with 
controls (0.33 (95% CI 0.32-0.35), p<0.0001) or chemotherapy (0.66 (95% CI 0.62-0.69), 
p<0.0001). Overall survival was also worse in PCCRC subjects compared with controls, with a 
median survival of 5.8 years in controls compared with 2.1 years in the PCCRC 6-12 months 
group, 2.0 years in the PCCRC 12-36 months group and 3.5 years in the PCCRC 36-60 months 
group (figure 1). Following adjusting for age, gender, co-morbidity and deprivation, survival 
outcomes remained worse for PCCRC subjects with a hazard ratio of 1.17 (95% CI 1.10- 
1.24)(p<0.0001), 1.26 (95% CI 1.20-1.31)(p<0.0001) and 1.20 (95% CI 1.13-1.27)(p<0.0001) 
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for the PCCRC 6-12 months, PCCRC 12-36 months and PCCRC 36-60 months respectively 
when compared with controls. 
 
Individual provider variables 
The influence of provider variables on PCCRC are shown in Table 4. There was a more than 
twofold variation in PCCRC rates between individual providers in England during the study 
period (figure 2). On univariate analysis, medium colonoscopy volume providers and low 
volume providers were both more likely to be associated with PCCRC than high volume 
providers. Following adjusting for other variables in the multivariate model an association 
with medium volume providers remained. BCSP accreditation status and the percentage of 
CRC diagnosed as an emergency were not associated with an increased risk of PCCRC. 
 
PCCRC rates over time 
The number of colonoscopies recorded in HES has increased by almost two fold over the 
study period. Despite the increase in colonoscopy numbers performed year on year, the 
annual rate of PCCRC has steadily fallen over the study period (p<0.0001)(figure 3). The 
annual PCCRC rate decreased from 13.8% in 2003-2004 to 11.9% by the end of study period 
in 2008-2009 with the reduction seen mainly in the PCCRC 6-12 months and PCCRC 12-36 
months groups. 
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Discussion 
 
The overall PCCRC rate of 12.1% in 67202 subjects in England between 2003 and 2009 
appears higher than previously published figures. However, some previous studies have 
calculated the PCCRC rate by only including CRC subjects with a colonoscopy up to 36 
months prior to diagnosis and the comparable figure from the present study is 8.3%. A 
Canadian study of 14,064 CRC subjects reported a PCCRC rate of 9.0% between 2000 and 
2005.[12] Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database 
in the USA, a PCCRC rate of 7.2% was reported between 1994 to 2005 from a study of 
57,839 CRC subjects.[19] A further population based study from Utah, USA with 2659 CRC 
subjects between 1995 and 2009 described a PCCRC rate of 6% when subjects with a 
colonoscopy up to 60 months prior to CRC diagnosis were included.[4] In Europe, two recent 
studies have reported much lower PCCRC rates. A Danish population based study between 
2000 to 2009 included 37,044 CRC subjects and concluded that only 2.7% of CRC subjects 
have had a colonoscopy that failed to diagnose CRC 1 to 5 years prior to diagnosis.[5] A 
second study from the Netherlands analysed 5107 CRC subjects between 2001 to 2010 from 
three providers and found a PCCRC rate of only 2.9% for subjects with a colonoscopy up to 
60 months prior to CRC diagnosis.[20] In addition to potential variations in subject and 
colonoscopy factors between the difference studies, the wide range of reported PCCRC 
rates are likely to be contributed to by methodological differences.[13] 
 
In the present study, PCCRC was associated with older subjects, female gender, an increased 
number of co-morbidities and right-sided CRC, which is in keeping with findings from other 
studies of PCCRC. [3, 12, 19, 21] The association between increasing age and PCCRC was less 
marked on multivariate analysis and this may relate to confounding from increasing co-
morbidity in the elderly. Elderly patients are more likely to have inadequate bowel 
preparation, thus reducing mucosal visualisation and detection of polyps and early CRC.[22, 
23] Female patients are more likely to have had previous abdominal and pelvic surgery, 
which may increase the technical difficulty of colonoscopy and impair patient tolerance, 
reducing the caecal intubation rate.[24] In addition to factors that have an adverse effect on 
caecal intubation rate, right sided CRC are more likely to arise from flat, non-polypoid 
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adenomatous lesions[20, 25] that poor bowel preparation may make difficult to detect. This 
will contribute to the association of right sided CRC with PCCRC. 
 
Over a fifth of PCCRC subjects had colonic polyps or polypectomy coded during the most 
recent colonoscopy prior to CRC diagnosis. This is higher than the average polypectomy rate 
in all colonoscopy procedures during the same period. Furthermore, polyp and polypectomy 
coding rates were highest in the PCCRC 12-36 months group. Prior polypectomy has been 
reported to double the risk of PCCRC[19], with up to 19% of CRC occurring in the same 
anatomic segment as a previously resected adenoma.[8] Paradoxically, colonoscopists with 
higher polypectomy rates have been reported to be associated with a lower risk of 
PCCRC[12, 19], presumably as they detect more polyps and remove them more completely 
than other colonoscopists. Incomplete polypectomy, or inadequate biopsy sampling of 
polyps, is therefore a key modifiable risk factor for PCCRC and ensuring adequate follow up 
and assessment following polypectomy may reduce PCCRC rates. 
 
PCCRC subjects appeared to have worse outcomes in terms of both treatment following 
diagnosis (surgery and chemotherapy) and overall survival. Previous studies have reported 
no survival difference between PCCRC subjects and controls[5, 21] with one recent study 
even reporting a survival benefit in the PCCRC subjects, which was likely to be due to earlier 
CRC stage at diagnosis in the PCCRC subjects.[4] In the current study, PCCRC subjects were 
older, had greater co-morbidities and were more likely to present with distant metastases 
within 12 months of diagnosis compared with controls. All these factors contributed to the 
reduced rates of curative surgery or palliative chemotherapy for PCCRC subjects and will 
have contributed to worse survival. Adjusting the survival analyses for differences in ages, 
gender, co-morbidity and deprivation still revealed worse survival for PCCRC subjects and, at 
least in England, PCCRC is clearly associated with worse survival.  Survival in PCCRC subjects 
would have been potentially better if earlier opportunities to diagnose their CRC had been 
taken.  
 
Previous studies have reported that PCCRC was not associated with endoscopist procedure 
volume[12] and that higher colonoscopy volumes may even be positively associated with 
PCCRC surprisingly.[19] In the current study, there was a large variation in PCCRC rates 
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between individual providers across England but PCCRC appeared to be associated with 
lower colonoscopy volume providers. This result should be interpreted with caution. We did 
not have access to colonoscopy quality indicators such as caecal intubation and adenoma 
detection rates that are likely to be potentially more important factors in PCCRC incidence.  
 
Colonoscopy undertaken during an emergency admission covered 10% of procedures 
examined and was associated with a lower risk of PCCRC at 9% compared with 14% for 
elective procedures. Patients presenting as an emergency may have more advanced 
colorectal cancer and therefore a lower chance of PCCRC.  
 
The annual PCCRC rate in England has fallen steadily over the study period from 13.8% to 
11.9%, at least partly due to improving colonoscopy standards over the corresponding time 
period. In 2003, a multi-regional audit in England including 9223 colonoscopies reported 
that mean caecal intubation rate was only 76.9%.[26] A subsequent national audit in 2011 
of 20085 colonoscopies found that the caecal intubation rate had improved to 92.3%.[1] The 
PCCRC rate is likely to continue to improve in recent years given changes in colonoscopy 
practice, including the recognition of the importance of minimum withdrawal times [27], 
bowel preparation improvements[28] and better endoscopic recognition of sessile serrated 
polyps[25], subsequent to the study period. 
 
The use of a national hospital dataset enabled us to undertake one of the largest PCCRC 
studies to date, including the vast majority of colonoscopies performed during a period of 
rising colonoscopy standards. The quality of diagnostic and procedural coding in HES has 
been previously investigated and there was a high concordance when compared with 
independent national data sources.[1, 10, 29] However, we did not have the opportunity to 
link our HES dataset directly to cancer registry data due to restrictions under which the data 
is held and therefore, in order to validate the methodology chosen, colonoscopy and CRC 
populations were compared with national cancer databases and a local data sample and 
revealed a good correlation. The completeness and accuracy of coding in HES is still a 
potential source of concern. For example, the diagnosis date may not be recorded 
accurately in HES due to the need for histological confirmation before CRC coding and 
therefore a colonoscopy within 6 months of CRC coding had to be considered the diagnostic 
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procedure. There are also limitations in HES concerning coding of colonoscopy procedures, 
polyps, polypectomy, presence of metastases, surgery and chemotherapy and the figures 
included may be an over or under estimate, though this is likely to affect PCCRC cases and 
controls equally. A further limitation is that key procedure information such as the bowel 
preparation quality, sedation doses, colonoscopist grade and specialty, extent of 
examination, completeness of polypectomy and number of biopsies taken are not recorded 
in HES and all may influence the PCCRC risk. Furthermore, due to the HES coding hierarchy, 
indication, presence of diverticular disease and history of abdominal or pelvic surgery may 
not be coded, partly due to under reporting by colonoscopists when significant pathology or 
CRC are found and again each may be important risk factors for PCCRC. As HES does not 
record polyp histology or the International Classification of Diseases for Oncology (ICD-O) 
codes, the lack of data on polyp and CRC histology and Duke’s staging further limits analysis 
of potential causes of PCCRC (de novo CRC, incomplete adenoma resection, missed lesion or 
biopsy failed to detect CRC) and survival in PCCRC subjects. 
 
In conclusion, the PCCRC rate was 12.1% in England between 2003 and 2009. PCCRC was 
associated with older age, female gender, increasing co-morbidity, procedure related 
factors (elective procedures and right sided CRC) and provider colonoscopy volume. Despite 
the encouraging fall in annual PCCRC rate over the study period, PCCRC rate should be a 
routinely measured endoscopy unit colonoscopy quality marker and potentially avoidable 
risk factors for PCCRC addressed. 
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Table 1. The characteristics of post-colonoscopy colorectal cancer cases and controls 
 
PCCRC 6-
12 months 
PCCRC 12-
36 months 
PCCRC 36-
60 months 
All PCCRC Controls 
Odds 
ratio 
95% CI p value 
Odds 
ratio 
95% CI p value 
Total subjects (number) Univariate Multivariate 
 1796 (2.7) 3772 (5.6) 2579 (3.8) 8147 (12.1) 59055 (87.9) - - - - - - 
Mean age SD (years) 
 71.5±11.4 70.9±11.7 69.8±10.8 70.7±11.4 70.2±11.4 - - <0.001    
Age group (number (%))    
Under 60 263 (3.2) 598 (7.3) 415 (5.1) 1276 (15.7) 9849 (16.7) Ref      
60-64 167 (2.0) 367 (4.5) 288 (3.5) 822 (10.1) 6749 (11.4) 0.94 0.86-1.03 0.1928 0.95  0.86-1.04 0.277 
65-69 217 (2.7) 531 (6.5) 435 (5.3) 1183 (14.5) 8810 (14.9) 1.04 0.95-1.13 0.4044 1.03  0.94-1.12 0.537 
70-74 344 (4.2) 648 (8.0) 488 (6.0) 1480 (18.2) 10229 (17.3) 1.12 1.03-1.21 0.0067 1.09  1.00-1.18 0.039 
75-79 359 (4.4) 678 (8.3) 499 (6.1) 1536 (18.9) 10698 (18.1) 1.11 1.02-1.20 0.0109 1.07  0.98-1.16 0.159 
80+ 446 (5.5) 950 (11.7) 454 (5.6) 1850 (22.7) 12720 (21.5) 1.12 1.04-1.21 0.0029 1.08  1.00-1.17 0.065 
Gender (number (%)) 
Male 974 (12.0) 1974 (24.2) 1340 (16.4) 4288 (52.6) 33057 (56.0) Ref - - Ref - - 
Female 822 (10.1) 1798 (22.1) 1239 (15.2) 3859 (47.4) 25998 (44.0) 1.14 1.09-1.20 <0.0001 1.13 1.08-1.19 <0.001 
Charlson co-morbidity index (number (%)) 
0 1514 (18.6) 3210 (39.4) 2235 (27.4) 6959 (85.4) 50663 (85.8) Ref - - Ref - - 
1-4 154 (1.9) 298 (3.7) 210 (2.6) 662 (8.1) 4764 (8.1) 1.01 0.93-1.10 0.7896 1.06  0.97-1.16 0.195 
5+ 128 (1.6) 264 (3.2) 134 (1.6) 526 (6.5) 3628 (6.1) 1.06 0.96-1.16 0.2641 1.16  1.05-1.28 0.003 
Deprivation quintile (number (%)) 
1 (most) 329 (4.0) 637 (7.8) 393 (4.8) 1359 (16.7) 10015 (17.0) Ref - - - - - 
2 365 (4.5) 740 (9.1) 499 (6.1) 1604 (19.7) 11258 (19.1) 1.05 0.97-1.13 0.2153 - - - 
3 333 (4.1) 782 (9.6) 551 (6.8) 1666 (20.4) 12399 (21.0) 0.99 0.91-1.07 0.8002 - - - 
4 387 (4.8) 784 (9.6) 568 (7.0) 1739 (21.3) 12642 (21.4) 1.01 0.94-1.09 0.7242 - - - 
5 (least) 381 (4.7) 823 (10.1) 566 (6.9) 1770 (21.7) 12620 (21.4) 1.03 0.96-1.11 0.3905 - - - 
Ethnicity (number (%)) 
Caucasian 
1656 
(20.3) 
3536 (43.4) 2467 (30.3) 7659 (94.0) 54512 (92.3) Ref - - - - - 
Asian 21 (0.3) 55 (0.7) 36 (0.4) 112 (1.4) 788 (1.3) 1.01 0.83-1.23 0.9097 - - - 
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Afro-
Caribbean 
25 (0.3) 53 (0.7) 27 (0.3) 105 (1.3) 823 (1.4) 0.91 0.74-1.11 0.3553 - - - 
Chinese 0 0 0 12 (0.1) 118 (0.2) 0.72 0.40-1.30 0.2865 - - - 
Mixed 0 0 0 18 (0.2) 160 (0.3) 0.80 0.49-1.30 0.3719 - - - 
Others 12 (0.1) 21 (0.3) 21 (0.3) 54 (0.7) 341 (0.6) 1.13 0.85-1.50 0.4156 - - - 
Unknown 74 (0.9) 95 (1.2) 18 (0.2) 187 (2.3) 2313 (3.9) 0.58 0.49-0.67 <0.0001 - - - 
Odds ratios with 95% confidence intervals and p values for PCCRC (all) compared with controls 
PCCRC – post-colonoscopy colorectal cancer 
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Table 2. The colonoscopy characteristics and findings of post-colonoscopy colorectal cancer cases and controls 
 
PCCRC 6-12 
months 
PCCRC 12-
36 months 
PCCRC 36-60 
months 
All PCCRC Controls 
Odds 
ratio 
95% CI p value 
Odds 
ratio 
95% CI p value 
Procedure day (number (%)) Univariate Multivariate 
Weekday 1736 (21.3) 3628 (44.5) 2486 (30.5) 7850 (96.4) 57249 (96.9) Ref - - - - - 
Weekend 60 (0.7) 144 (1.8) 93 (1.1) 297 (3.6) 1806 (3.1) 1.19 1.06-1.36 0.0044 - - - 
Procedure type (number (%))    
Elective 1622 (19.9) 3473 (42.6) 2455 (30.1) 7550 (92.7) 52605 (89.1) Ref - - Ref - - 
Emergency 174 (2.1) 299 (3.7) 124 (1.5) 597 (7.3) 6450 (10.9) 0.64 0.59-0.70 <0.0001 0.54 0.59-0.69 <0.0001 
Colorectal cancer location (number (%))    
Left sided 897 (11.0) 1754 (21.5) 1260 (15.5) 3911 (48.0) 34703 (58.8) Ref - - Ref - - 
Right sided 535 (6.6) 1242 (15.2) 919 (11.3) 2696 (33.1) 20751 (35.1) 1.15 1.09-1.21 <0.0001 1.17  1.11-1.23 <0.0001 
Unknown/ 
overlapping sites 
364 (4.5) 776 (9.5) 400 (4.9) 1540 (18.9) 3601 (6.1) 3.79 3.54-4.06 <0.0001 3.72  3.46-3.99 <0.0001 
Polyp/ polypectomy coded (number (%))    
Polyp coded 491 (6.0) 742 (9.1) 523 (6.4) 1756 (21.6) 141799* (9.8) 2.52+ 2.39-2.65+ <0.0001+ - - - 
No polyp coded 1305 (16.0) 3030 (37.2) 2056 (25.2) 6391 (78.4) 1300714* (90.2) Ref - - - - - 
Polypectomy coded 348 (4.3) 669 (8.2) 523 (6.4) 1540 (18.9) 162364* (11.3) 1.82+ 1.72-1.92+ <0.0001+ - - - 
No polypectomy 
coded 
1448 (17.8) 3103 (38.1) 2056 (25.2) 6607 (81.1) 1280150* (89.7) Ref - - - - - 
Odds ratios with 95% confidence intervals and p values for all PCCRC compared with controls 
PCCRC – post-colonoscopy colorectal cancer 
* From all colonoscopies 
+ Univariate analysis comparing all PCCRC with all colonoscopies during study period. 
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Table 3. The prevalence of metastases within 12 months of colorectal cancer diagnosis in post-colonoscopy colorectal cancer cases and controls 
 
PCCRC 6-12 
months 
PCCRC 12-36 
months 
PCCRC 36-60 
months 
All PCCRC Controls 
Odds 
ratio 
95% CI p value 
Odds 
ratio 
95% CI p value 
Subjects with metastases within 12 months of diagnosis (number (%)) Univariate Multivariate 
Liver metastases 276 (3.4) 619 (7.6) 365 (4.5) 1260 (15.5) 8545 (14.5) 1.08 1.01-1.15 0.017 0.97  0.91-1.05 0.486 
Lung metastases 154 (1.9) 345 (4.2) 182 (2.2) 681 (8.4) 3104 (5.3) 1.64 1.51-1.79 <0.0001 1.61  1.46-1.77 <0.0001 
Peritoneal 
metastases 
75 (0.9) 166 (2.0) 102 (1.3) 343 (4.2) 1903 (3.2) 1.32 1.17-1.48 <0.0001 1.27  1.12-1.44 <0.0001 
Bone metastases 45 (0.6) 106 (1.3) 78 (1.0) 229 (2.8) 678 (1.1) 2.49 2.14-2.90 <0.0001 2.21  1.88-2.60 <0.0001 
Lymph node 
metastases 
136 (1.7) 282 (3.5) 231 (2.8) 649 (8.0) 6459 (10.9) 0.70 0.65-0.76 <0.0001 0.75  0.69-0.82 <0.0001 
Treatment outcome following diagnosis (number (%))    
Surgery 791 (9.7) 1661 (20.4) 1337 (16.4) 3789 (46.5) 42790 (72.5) 0.33 0.32-0.35 <0.0001 - - - 
Chemotherapy 422 (5.2) 911 (11.2) 594 (7.3) 1927 (23.7) 18908 (32.0) 0.66 0.62-0.69 <0.0001 - - - 
Odds ratios with 95% confidence intervals and p values for PCCRC (all) compared with controls 
PCCRC – post-colonoscopy colorectal cancer 
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Table 4. The influence of provider variables on post-colonoscopy colorectal cancer 
 
PCCRC 6-12 
months 
PCCRC 12-
36 months 
PCCRC 36-60 
months 
All PCCRC Controls 
Odds 
ratio 
95% CI p value 
Odds 
ratio 
95% CI p value 
Colonoscopy volume by NHS provider (number (%)) Univariate Multivariate 
High volume providers 
(>1680 pa) 
955 (11.7) 1993 (24.5) 1415 (17.4) 4363 (53.6) 33353 (56.5) Ref - - Ref - - 
Medium volume providers 704 (8.6) 1486 (18.2) 994 (12.2) 3184 (39.1) 21942 (37.2) 1.11 1.06-1.16 <0.0001 1.13 1.01-1.27 0.035 
Low volume providers (<747 
pa) 
137 (1.7) 293 (3.6) 170 (2.1) 600 (7.4) 3760 (6.4) 1.22 1.11-1.34 <0.0001 1.05  0.98-1.12 0.161 
BCSP status (number (%)) 
BCSP provider 959 (11.8) 2064 (25.3) 1396 (17.1) 4419 (54.2) 31780 (53.8) Ref - - - - - 
Non-BCSP provider 837 (10.3) 1708 (21.0) 1183 (14.5) 3728 (45.8) 27275 (46.2) 0.98 0.94-1.03 0.4690 0.96  0.90-1.03 0.255 
Percentage of CRC diagnosed during an emergency admission by NHS provider (number (%)) 
Low percentage providers 
(<27.3%) 
408 (5.0) 848 (10.4) 629 (7.7) 1885 (23.1) 14270 (24.2) 0.91 0.84-0.98 0.0115 0.96  0.87- 1.06 0.443 
Medium percentage 
providers 
1068 (13.1) 2273 (27.9) 1530 (18.8) 4871 (59.8) 35211 (59.6) 0.95 0.89-1.01 0.1299 0.96  0.85-1.09 0.531 
High percentage providers 
(>33.9%) 
320 (3.9) 651 (8.0) 420 (5.2) 1391 (17.1) 9572 (16.2) Ref - - Ref - - 
Odds ratios with 95% confidence intervals and p values for PCCRC (all) compared with controls 
PCCRC – post-colonoscopy colorectal cancer 
BCSP – Bowel Cancer Screening Program 
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Figure 1. Post-colonoscopy colorectal cancer rates by individual provider in England 
between 2003 and 2009. 
 
Figure 2. Unadjusted survival following colorectal cancer diagnosis in post-colonoscopy 
colorectal cancer cases and control subjects. 
 
Figure 3 Post-colonoscopy colorectal cancer rates and colonoscopy volume in England by 
year. 
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Appendix 1 - OPCS-4 codes for colonoscopy 
H20.1 Snare polypectomy 
H20.6 Polypectomy with colonoscopy 
H22.1 Diagnostic fibreoptic endoscopic examination of colon and biopsy of lesion of colon 
H22.8 Other specified diagnostic endoscopic examination of colon 
H22.9 Unspecified diagnostic endoscopic examination of colon 
 
Appendix 2 - ICD-10 codes for colorectal cancers 
C18 Malignant neoplasm of colon - excluding C18.1 (malignant neoplasm of appendix) 
C19 Malignant neoplasm of rectosigmoid junction 
C20 Malignant neoplasm of rectum 
 
Appendix 3 – ICD-10 codes for colorectal cancer (CRC) sites 
Right sided CRC 
C18.0 Caecum, Ileocaecal valve 
C18.2 Ascending colon 
C18.3 Hepatic flexure 
C18.4 Transverse colon 
 
Left sided CRC 
C18.5 Splenic flexure 
C18.6 Descending colon 
C18.7 Sigmoid colon 
C19 Rectosigmoid junction 
C20 Rectum 
 
Unspecified CRC location 
C18.8 Overlapping lesion of colon 
C18.9 Colon, unspecified 
 
Appendix 4 - ICD-10 codes for colorectal polyps 
D12.0 Caecal polyp(s) 
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D12.2 Ascending colon polyp(s) 
D12.3 Transverse colon, hepatic flexure, splenic flexure polyp(s) 
D12.4 Descending colon polyp(s) 
D12.5 Sigmoid colon polyp(s) 
D12.6 Colon, site unspecified polyp(s) 
D12.7 Rectosigmoid junction polyp(s) 
D12.8 Rectal polyp(s) 
 
Appendix 5 - ICD-10 codes for metastases 
C77.1 Intrathoracic lymph nodes 
C77.2 Intra-abdominal lymph nodes 
C77.4 Inguinal and lower limb lymph nodes 
C77.5 Intrapelvic lymph nodes 
C78.0 Secondary malignant neoplasm of lung 
C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum 
C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct 
C79.5 Secondary malignant neoplasm of bone and bone marrow 
C34 Malignant neoplasm of bronchus and lung 
C48 Malignant neoplasm of retroperitoneum and peritoneum 
C22 Malignant neoplasm of liver 
C40-C41 Malignant neoplasms of bone and articular cartilage 
 
Appendix 6- OPCS-4 codes for surgical procedures 
H04 Total excision of colon and rectum 
H05 Total excision of colon 
H06 Extended excision of right hemicolon 
H07 Other excision of right hemicolon 
H08 Excision of transverse colon 
H09 Excision of left hemicolon 
H10 Excision of sigmoid colon 
H11 Other excision of colon 
H29 Subtotal excision of colon 
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H33 Excision of rectum 
H40 Operations on rectum through anal sphincter 
H122 Excision of lesion of colon NEC 
H123 Destruction of lesion of colon NEC 
H128 Other specified extirpation of lesion of colon 
H129 Unspecified extirpation of lesion of colon 
H341 Open excision of lesion of rectum 
H345 Open destruction of lesion of rectum 
H348 Other specified open extirpation of lesion of rectum 
H349 Unspecified open extirpation of lesion of rectum 
H402 Trans-sphincteric excision of lesion of rectum 
H403 Trans-sphincteric destruction of lesion of rectum 
OPCS-4 codes for chemotherapy 
X70 Procurement of drugs for chemotherapy for neoplasm in Bands 1-5 
X71 Procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
X72 Delivery of Chemotherapy for neoplasm 
X73 Delivery of oral chemotherapy for neoplasm 
X352 Intravenous chemotherapy 
X384 Subcutaneous chemotherapy 
X373 Intramuscular chemotherapy 
Z082 Follow up examination after chemotherapy for malignant neoplasm 
Z511 Chemotherapy session for neoplasm 
Z542 Convalescence following chemotherapy 
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